DNA sequencing of cancer: What have we learned?

Annual Review of Medicine

Volumn 65, Issue , 2014, Pages 63-79

  Chmielecki, Juliann ^a,b   Meyerson, Matthew ^a,b,c,d  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cancer; Genomics; Mutations; Pathways; Rearrangements

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TRANSCRIPTION FACTOR;

CANCER GENETICS; CELL CYCLE; CHROMATIN; DNA MODIFICATION; DNA SEQUENCE; EPIGENETICS; GENE MUTATION; GENE REARRANGEMENT; GENETIC TRANSCRIPTION; GENOMICS; HUMAN; METABOLISM; NONHUMAN; PRIORITY JOURNAL; REVIEW; RNA PROCESSING; SIGNAL TRANSDUCTION;

CELL CYCLE; DNA MUTATIONAL ANALYSIS; EPIGENESIS, GENETIC; GENE REARRANGEMENT; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASMS; ONCOGENE FUSION; ONCOGENE PROTEIN V-AKT; RNA; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 84899740340     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-060712-200152     Document Type: Review

References (147)

1. Lander ES, Linton LM, Birren B, et al. 2001. Initial sequencing and analysis of the human genome. Nature 409:860-921 (Pubitemid 32165345)
2. Venter JC, Adams MD, Myers EW, et al. 2001. The sequence of the human genome. Science 291:1304-51 (Pubitemid 32173090)
3. Mwenifumbo JC, Marra MA. 2013. Cancer genome-sequencing study design. Nat. Rev. Genet. 14:321-32
4. Gnirke A, Melnikov A, Maguire J, et al. 2009. Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. Nat. Biotechnol. 27:182-89
5. Cibulskis K, Lawrence MS, Carter SL, et al. 2013. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31:213-19
6. Lawrence MS, Stojanov P, Polak P, et al. 2013. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499:214-18
7. Hammerman PS, LawrenceMS, Voet D, et al. 2012. Comprehensive genomic characterization of squamous cell lung cancers. Nature 489:519-25
8. Hodis E, Watson IR, Kryukov GV, et al. 2012. A landscape of driver mutations in melanoma. Cell 150:251-63
9. ImielinskiM, Berger AH, Hammerman PS, et al. 2012. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150:1107-20
10. Mok TS, Wu YL, Thongprasert S, et al. 2009. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361:947-57
11. Rosell R, Moran T, Queralt C, et al. 2009. Screening for epidermal growth factor receptor mutations in lung cancer. N. Engl. J. Med. 361:958-67
12. Chapman PB, Hauschild A, Robert C, et al. 2011. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364:2507-16
13. LynchTJ, BellDW, Sordella R, et al. 2004. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350:2129-39
14. Paez JG, Janne PA, Lee JC, et al. 2004.EGFRmutations in lung cancer: correlationwith clinical response to gefitinib therapy. Science 304:1497-500 (Pubitemid 38720929)
15. Pao W, Miller V, Zakowski M, et al. 2004. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. USA 101:13306-11
16. Stephens P, Hunter C, Bignell G, et al. 2004. Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 431:525-26
17. Ross JS, WangK, Sheehan CE, et al. 2013. Relapsed classicE-cadherin (CDH1)-mutated invasive lobular breast cancer shows a high frequency of HER2 (ERBB2) gene mutations. Clin. Cancer Res. 19:2668-76
18. TCGA. 2008. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061-68
19. Demetri GD. 2001. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options. Semin. Oncol. 28:19-26
20. CorlessCL, Schroeder A, Griffith D, et al. 2005. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J. Clin. Oncol. 23:5357-64
21. Dutt A, Salvesen HB, Chen TH, et al. 2008. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc. Natl. Acad. Sci. USA 105:8713-17
22. Pollock PM, Gartside MG, Dejeza LC, et al. 2007. Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene 26:7158-62 (Pubitemid 350059681)
23. van Rhijn BW, van Tilborg AA, Lurkin I, et al. 2002. Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders. Eur. J. Hum. Genet. 10:819-24
24. Liao R, Jung J, Tchaicha J, et al. 2013. Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. Cancer Res. 73:5195-205
25. Hammerman PS, Sos ML, Ramos AH, et al. 2011. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov. 1:78-89
26. Levine RL, Wadleigh M, Cools J, et al. 2005. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7:387-97 (Pubitemid 40544655)
27. Pugh TJ, Morozova O, Attiyeh EF, et al. 2013. The genetic landscape of high-risk neuroblastoma. Nat. Genet. 45:279-84
28. Gherardi E, Birchmeier W, Birchmeier C, et al. 2012. TargetingMET in cancer: rationale and progress. Nat. Rev. Cancer 12:89-103
29. Seo JS, Ju YS, Lee WC, et al. 2012. The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res. 22:2109-19
30. Arteaga CL, Sliwkowski MX, Osborne CK, et al. 2012. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat. Rev. Clin. Oncol. 9:16-32
31. Patil S, Chamberlain RS. 2012. Neoplasms associated with germline and somatic NF1 gene mutations. Oncologist 17:101-16
32. Davies H, Bignell GR, Cox C, et al. 2002. Mutations of the BRAF gene in human cancer. Nature 417:949-54 (Pubitemid 34716871)
33. Solit DB, Garraway LA, Pratilas CA, et al. 2006. BRAF mutation predicts sensitivity to MEK inhibition. Nature 439:358-62 (Pubitemid 43128863)
34. Dahlman KB, Xia J, Hutchinson K, et al. 2012. BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. Cancer Discov. 2:791-97
35. Ellis MJ, Ding L, Shen D, et al. 2012. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 486:353-60
36. Marks JL, Gong Y, Chitale D, et al. 2008. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 68:5524- 28
37. Stephens PJ, Tarpey PS, Davies H, et al. 2012. The landscape of cancer genes and mutational processes in breast cancer. Nature 486:400-4
38. Banerji S, Cibulskis K, Rangel-Escareno C, et al. 2012. Sequence analysis ofmutations and translocations across breast cancer subtypes. Nature 486:405-9
39. CheungHW, Du J, Boehm JS, et al. 2011. Amplification ofCRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers. Cancer Discov. 1:608-25
40. Samuels Y, Wang Z, Bardelli A, et al. 2004. High frequency of mutations of the PIK3CA gene in human cancers. Science 304:554 (Pubitemid 38541907)
41. Parsons DW, Jones S, Zhang X, et al. 2008. An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807-12
42. Kandoth C, Schultz N, Cherniack AD, et al. 2013. Integrated genomic characterization of endometrial carcinoma. Nature 497:67-73
43. Brastianos PK, Horowitz PM, Santagata S, et al. 2013. Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat. Genet. 45:285-89
44. Bleeker FE, Felicioni L, Buttitta F, et al. 2008. AKT1(E17K) in human solid tumours. Oncogene 27:5648- 50
45. Malanga D, Scrima M, De Marco C, et al. 2008. Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung. Cell Cycle 7:665-69 (Pubitemid 351499006)
46. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, et al. 2008. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res. 68:6084-91
47. Carpten JD, Faber AL, Horn C, et al. 2007. A transformingmutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448:439-44 (Pubitemid 47123510)
48. Soung YH, Lee JW, Nam SW, et al. 2006. Mutational analysis of AKT1, AKT2 and AKT3 genes in common human carcinomas. Oncology 70:285-89
49. Davies MA, Stemke-Hale K, Tellez C, et al. 2008. A novel AKT3 mutation in melanoma tumours and cell lines. Br. J. Cancer 99:1265-68
50. Cairns RA, Harris IS, Mak TW. 2011. Regulation of cancer cell metabolism. Nat. Rev. Cancer 11:85-95
51. Yan H, Parsons DW, Jin G, et al. 2009. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360:765-73
52. Mardis ER, Ding L, Dooling DJ, et al. 2009. Recurring mutations found by sequencing an acute myeloid leukemia genome. N. Engl. J. Med. 361:1058-66
53. Amary MF, Bacsi K, Maggiani F, et al. 2011. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J. Pathol. 224:334-43
54. Wingo SN, Gallardo TD, Akbay EA, et al. 2009. Somatic LKB1 mutations promote cervical cancer progression. PLoS One 4:e5137
55. Ley TJ, Ding L, Walter MJ, et al. 2010. DNMT3A mutations in acute myeloid leukemia. N. Engl. J. Med. 363:2424-33
56. Walter MJ, DingL, Shen D, et al. 2011. RecurrentDNMT3Amutations in patientswithmyelodysplastic syndromes. Leukemia 25:1153-58
57. Delhommeau F, Dupont S, Della Valle V, et al. 2009. Mutation in TET2 in myeloid cancers. N. Engl. J. Med. 360:2289-301
58. Langemeijer SM, Kuiper RP, Berends M, et al. 2009. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat. Genet. 41:838-42
59. Jones S, Wang TL, Shih Ie M, et al. 2010. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 330:228-31
60. Wiegand KC, Shah SP, Al-AghaO M, et al. 2010.ARID1Amutations in endometriosis-associated ovarian carcinomas. N. Engl. J. Med. 363:1532-43
61. TCGA. 2011. Integrated genomic analyses of ovarian carcinoma. Nature 474:609-15
62. Fujimoto A, Totoki Y, Abe T, et al. 2012. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat. Genet. 44:760-64
63. Huang J, DengQ, Wang Q, et al. 2012. Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma. Nat. Genet. 44:1117-21
64. Balbas-Martinez C, Rodriguez-Pinilla M, Casanova A, et al. 2013. ARID1A alterations are associated with FGFR3-wild type, poor-prognosis, urothelial bladder tumors. PLoS One 8:e62483
65. Wiegand KC, Lee AF, Al-Agha OM, et al. 2011. Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas. J. Pathol. 224:328-33
66. Dulak AM, Stojanov P, Peng S, et al. 2013. Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat. Genet. 45:478-86
67. Biankin AV, Waddell N, Kassahn KS, et al. 2012. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491:399-405
68. Jiao Y, Shi C, Edil BH, et al. 2011. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 331:1199-203
69. Cheung NK, Zhang J, Lu C, et al. 2012. Association of age at diagnosis and geneticmutations in patients with neuroblastoma. JAMA 307:1062-71
70. Biegel JA, Zhou JY, Rorke LB, et al. 1999. Germ-line and acquiredmutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res. 59:74-79 (Pubitemid 29062960)
71. Peifer M, Fernandez-Cuesta L, Sos ML, et al. 2012. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat. Genet. 44:1104-10
72. Stransky N, Egloff AM, Tward AD, et al. 2011. The mutational landscape of head and neck squamous cell carcinoma. Science 333:1157-60
73. Gui Y, Guo G, Huang Y, et al. 2011. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat. Genet. 43:875-78
74. Morin RD, Mendez-Lago M, Mungall AJ, et al. 2011. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476:298-303
75. Marks PA. 2010. The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin. Investig. Drugs 19:1049-66
76. Barbieri CE, Demichelis F, Rubin MA. 2012. Molecular genetics of prostate cancer: emerging appreciation of genetic complexity. Histopathology 60:187-98
77. TCGA. 2012. Comprehensive molecular portraits of human breast tumours. Nature 490:61-70
78. Roberts NJ, Jiao Y, Yu J, et al. 2012. ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov. 2:41-46
79. Heravi-Moussavi A, Anglesio MS, Cheng SW, et al. 2012. Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers. N. Engl. J. Med. 366:234-42
80. Hill DA, Ivanovich J, Priest JR, et al. 2009. DICER1 mutations in familial pleuropulmonary blastoma. Science 325:965
81. Barbieri CE, Baca SC, Lawrence MS, et al. 2012. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat. Genet. 44:685-89
82. Bass AJ, Watanabe H, Mermel CH, et al. 2009. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat. Genet. 41:1238-42
83. Weir BA, Woo MS, Getz G, et al. 2007. Characterizing the cancer genome in lung adenocarcinoma. Nature 450:893-98 (Pubitemid 350231325)
84. Salari K, Spulak ME, Cuff J, et al. 2012. CDX2 is an amplified lineage-survival oncogene in colorectal cancer. Proc. Natl. Acad. Sci. USA 109:E3196-205
85. Palles C, Cazier JB, Howarth KM, et al. 2013. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat. Genet. 45:136-44
86. Wang L, LawrenceMS, Wan Y, et al. 2011. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N. Engl. J. Med. 365:2497-506
87. Rossi D, BruscagginA, Spina V, et al. 2011. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. Blood 118:6904-8
88. Quesada V, Conde L, Villamor N, et al. 2012. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat. Genet. 44:47-52
89. Patnaik MM, Lasho TL, Hodnefield JM, et al. 2012. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood 119:569-72
90. Yoshida K, Sanada M, Shiraishi Y, et al. 2011. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 478:64-69
91. Papaemmanuil E, Cazzola M, Boultwood J, et al. 2011. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N. Engl. J. Med. 365:1384-95
92. Graubert TA, Shen D, Ding L, et al. 2012. Recurrent mutations in theU2AF1splicing factor in myelodysplastic syndromes. Nat. Genet. 44:53-57
93. Harbour JW, Roberson ED, Anbunathan H, et al. 2013. Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma. Nat. Genet. 45:133-35
94. Druker BJ, Talpaz M, Resta DJ, et al. 2001. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344:1031-37
95. Soda M, Choi YL, Enomoto M, et al. 2007. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448:561-66 (Pubitemid 47206930)
96. Kohno T, Ichikawa H, Totoki Y, et al. 2012. KIF5B-RET fusions in lung adenocarcinoma. Nat. Med. 18:375-77
97. Takeuchi K, Soda M, Togashi Y, et al. 2012. RET, ROS1 and ALK fusions in lung cancer. Nat. Med. 18:378-81
98. Lipson D, Capelletti M, Yelensky R, et al. 2012. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat. Med. 18:382-84
99. Bergethon K, Shaw AT, Ou SH, et al. 2012. ROS1 rearrangements define a unique molecular class of lung cancers. J. Clin. Oncol. 30:863-70
100. Ju YS, LeeWC, Shin JY, et al. 2012.AtransformingKIF5B andRETgene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res. 22:436-45
101. Kwak EL, Bang YJ, Camidge DR, et al. 2010. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363:1693-703
102. Drilon A, Wang L, Hasanovic A, et al. 2013. Response to cabozantinib in patients with RET fusionpositive lung adenocarcinomas. Cancer Discov. 3:630-35
103. Ozawa T, Brennan CW, Wang L, et al. 2010. PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas. Genes Dev. 24:2205-18
104. Wu YM, Su F, Kalyana-Sundaram S, et al. 2013. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov. 3:636-47
105. Zhang J, Wu G, Miller CP, et al. 2013. Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat. Genet. 45:602-12
106. Jones DT, Kocialkowski S, Liu L, et al. 2008. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res. 68:8673-77
107. Ramkissoon LA, Horowitz PM, Craig JM, et al. 2013. Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1. Proc. Natl. Acad. Sci. USA 110:8188-93
108. PerssonM, Andren Y, Mark J, et al. 2009. Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc. Natl. Acad. Sci. USA 106:18740-44
109. Chmielecki J, Crago AM, Rosenberg M, et al. 2013. Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors. Nat. Genet. 45:131-32
110. Robinson DR, Wu YM, Kalyana-Sundaram S, et al. 2013. Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. Nat. Genet. 45:180-85
111. Tomlins SA, Rhodes DR, Perner S, et al. 2005. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310:644-48 (Pubitemid 41528150)
112. TCGA. 2013. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 368:2059-74
113. Stephens PJ, Greenman CD, Fu B, et al. 2011. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 144:27-40
114. Baca SC, Prandi D, Lawrence MS, et al. 2013. Punctuated evolution of prostate cancer genomes. Cell 153:666-77
115. Kostic AD, Ojesina AI, Pedamallu CS, et al. 2011. PathSeq: software to identify or discover microbes by deep sequencing of human tissue. Nat. Biotechnol. 29:393-96
116. Feng H, Shuda M, Chang Y, et al. 2008. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 319:1096-100 (Pubitemid 351300792)
117. Castellarin M, Warren RL, Freeman JD, et al. 2012. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res. 22:299-306
118. Kostic AD, GeversD, Pedamallu CS, et al. 2012. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res. 22:292-98
119. Landau DA, Carter SL, Stojanov P, et al. 2013. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 152:714-26
120. Gerlinger M, Rowan AJ, Horswell S, et al. 2012. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366:883-92
121. Yachida S, Jones S, Bozic I, et al. 2010. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467:1114-17
122. Navin N, Kendall J, Troge J, et al. 2011. Tumour evolution inferred by single-cell sequencing. Nature 472:90-94
123. Hou Y, Song L, Zhu P, et al. 2012. Single-cell exome sequencing and monoclonal evolution of a JAK2- negative myeloproliferative neoplasm. Cell 148:873-85
124. Xu X, Hou Y, Yin X, et al. 2012. Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor. Cell 148:886-95
125. Huang FW, Hodis E, Xu MJ, et al. 2013. Highly recurrent TERT promoter mutations in human melanoma. Science 339:957-59
126. Horn S, Figl A, Rachakonda PS, et al. 2013. TERT promoter mutations in familial and sporadic melanoma. Science 339:959-61
127. Cortes JE, Kim DW, Kantarjian HM, et al. 2012. Bosutinib versus imatinib in newly diagnosed chronicphase chronic myeloid leukemia: results from the BELA trial. J. Clin. Oncol. 30:3486-92
128. Saglio G, Kim DW, Issaragrisil S, et al. 2010. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 362:2251-59
129. Kantarjian H, Shah NP, Hochhaus A, et al. 2010. Dasatinib versus imatinib in newly diagnosed chronicphase chronic myeloid leukemia. N. Engl. J. Med. 362:2260-70
130. Hauschild A, Grob JJ, Demidov LV, et al. 2012. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380:358-65
131. Rosell R, Carcereny E, Gervais R, et al. 2012. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 13:239-46
132. Sequist LV, Yang JC, Yamamoto N, et al. 2013. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J. Clin. Oncol. doi:10.1200/JCO.2012.44.2806
133. Van Cutsem E, Kohne CH, Hitre E, et al. 2009. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360:1408-17
134. Van Cutsem E, Peeters M, Siena S, et al. 2007. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J. Clin. Oncol. 25:1658-64
135. Gozgit JM, WongMJ, Moran L, et al. 2012. Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models. Mol. Cancer Ther. 11:690-99
136. Demetri GD, van Oosterom AT, Garrett CR, et al. 2006. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368:1329-38 (Pubitemid 44528723)
137. Demetri GD, Reichardt P, Kang YK, et al. 2013. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:295-302
138. van der Graaf WT, Blay JY, Chawla SP, et al. 2012. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379:1879-86
139. Rodig SJ, Shapiro GI. 2010. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases. Curr. Opin. Investig. Drugs 11:1477-90
140. Tumorscape: http://www.broadinstitute.org/tumorscape/. Beroukhim R, Mermel CH, Porter D, et al. 2010. The landscape of somatic copy-number alteration across human cancers. Nature 463:899-905
141. Catalog of Somatic Mutations in Cancer (COSMIC): http://cancer.sanger.ac. uk/cosmic. Forbes SA, Bindal N, Bamford S, et al. 2011. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 39:D945-50
142. Firehose Genome Data Analysis Center (GDAC): http://gdac.broadinstitute. org
143. University of California Santa Cruz (UCSC) Genome Browser: http://genome.ucsc.edu. Goldman M, Craft B, Swatloski T, et al. 2013. The UCSC Cancer Genomics Browser: update 2013. Nucleic Acids Res. 41:D949-54
144. Memorial Sloan-Kettering Cancer Center cBio Portal: http://www. cbioportal.org. Cerami E, Gao J, Dogrusoz U, et al. 2012. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2:401-4 Suggested complementary reviews on the cancer genome and DNA sequencing in cancer
145. Garraway LA, Lander ES. 2013. Lessons from the cancer genome. Cell 153:17-37
146. Vogelstein B, Papadopoulos N, Velculescu VE, et al. 2013. Cancer genome landscapes. Science 339:1546-58
147. Stratton MR. 2011. Exploring the genomes of cancer cells: progress and promise. Science 331:1553-58